Annual CFI
-$34.65 M
-$116.34 M-142.41%
31 December 2023
Summary:
Prelude Therapeutics Incorporated annual cash flow from investing activities is currently -$34.65 million, with the most recent change of -$116.34 million (-142.41%) on 31 December 2023. During the last 3 years, it has fallen by -$34.02 million (-5479.07%). PRLD annual CFI is now -142.41% below its all-time high of $81.69 million, reached on 31 December 2022.PRLD Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$10.73 M
-$15.39 M-58.91%
30 September 2024
Summary:
Prelude Therapeutics Incorporated quarterly cash flow from investing activities is currently $10.73 million, with the most recent change of -$15.39 million (-58.91%) on 30 September 2024. Over the past year, it has dropped by -$4.31 million (-28.66%). PRLD quarterly CFI is now -74.17% below its all-time high of $41.55 million, reached on 31 March 2022.PRLD Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
$75.81 M
-$4.31 M-5.38%
30 September 2024
Summary:
Prelude Therapeutics Incorporated TTM cash flow from investing activities is currently $75.81 million, with the most recent change of -$4.31 million (-5.38%) on 30 September 2024. Over the past year, it has increased by +$116.84 million (+284.78%). PRLD TTM CFI is now -7.20% below its all-time high of $81.69 million, reached on 31 December 2022.PRLD TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PRLD Cash From Investing Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -142.4% | -28.7% | +284.8% |
3 y3 years | -5479.1% | +104.1% | +128.9% |
5 y5 years | -6449.3% | - | - |
PRLD Cash From Investing High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3 years | -142.4% | +86.9% | -74.2% | +104.1% | -7.2% | +128.7% |
5 y | 5 years | -142.4% | +86.9% | -74.2% | +104.1% | -7.2% | +128.7% |
alltime | all time | -142.4% | +86.9% | -74.2% | +104.1% | -7.2% | +128.7% |
Prelude Therapeutics Incorporated Cash From Investing History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sept 2024 | - | $10.73 M(-58.9%) | $75.81 M(-5.4%) |
June 2024 | - | $26.12 M(-16.3%) | $80.12 M(-474.0%) |
Mar 2024 | - | $31.22 M(+303.6%) | -$21.42 M(-38.2%) |
Dec 2023 | -$34.65 M(-142.4%) | $7.74 M(-48.6%) | -$34.65 M(-15.6%) |
Sept 2023 | - | $15.04 M(-119.9%) | -$41.03 M(+19.0%) |
June 2023 | - | -$75.43 M(-519.1%) | -$34.47 M(-159.3%) |
Mar 2023 | - | $18.00 M(+1228.3%) | $58.14 M(-28.8%) |
Dec 2022 | $81.69 M | $1.35 M(-93.7%) | $81.69 M(+4.0%) |
Sept 2022 | - | $21.61 M(+25.8%) | $78.53 M(-138.6%) |
June 2022 | - | $17.18 M(-58.6%) | -$203.71 M(-7.9%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2022 | - | $41.55 M(-2403.1%) | -$221.27 M(-16.1%) |
Dec 2021 | -$263.80 M(>+9900.0%) | -$1.80 M(-99.3%) | -$263.80 M(+0.6%) |
Sept 2021 | - | -$260.63 M(>+9900.0%) | -$262.33 M(>+9900.0%) |
June 2021 | - | -$381.00 K(-61.4%) | -$1.87 M(+22.2%) |
Mar 2021 | - | -$986.00 K(+199.7%) | -$1.53 M(+145.9%) |
Dec 2020 | -$621.00 K(-20.4%) | -$329.00 K(+93.5%) | -$621.00 K(+112.7%) |
Sept 2020 | - | -$170.00 K(+304.8%) | -$292.00 K(+139.3%) |
June 2020 | - | -$42.00 K(-47.5%) | -$122.00 K(+52.5%) |
Mar 2020 | - | -$80.00 K | -$80.00 K |
Dec 2019 | -$780.00 K(+47.4%) | - | - |
Dec 2018 | -$529.00 K | - | - |
FAQ
- What is Prelude Therapeutics Incorporated annual cash flow from investing activities?
- What is the all time high annual CFI for Prelude Therapeutics Incorporated?
- What is Prelude Therapeutics Incorporated annual CFI year-on-year change?
- What is Prelude Therapeutics Incorporated quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Prelude Therapeutics Incorporated?
- What is Prelude Therapeutics Incorporated quarterly CFI year-on-year change?
- What is Prelude Therapeutics Incorporated TTM cash flow from investing activities?
- What is the all time high TTM CFI for Prelude Therapeutics Incorporated?
- What is Prelude Therapeutics Incorporated TTM CFI year-on-year change?
What is Prelude Therapeutics Incorporated annual cash flow from investing activities?
The current annual CFI of PRLD is -$34.65 M
What is the all time high annual CFI for Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated all-time high annual cash flow from investing activities is $81.69 M
What is Prelude Therapeutics Incorporated annual CFI year-on-year change?
Over the past year, PRLD annual cash flow from investing activities has changed by -$116.34 M (-142.41%)
What is Prelude Therapeutics Incorporated quarterly cash flow from investing activities?
The current quarterly CFI of PRLD is $10.73 M
What is the all time high quarterly CFI for Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated all-time high quarterly cash flow from investing activities is $41.55 M
What is Prelude Therapeutics Incorporated quarterly CFI year-on-year change?
Over the past year, PRLD quarterly cash flow from investing activities has changed by -$4.31 M (-28.66%)
What is Prelude Therapeutics Incorporated TTM cash flow from investing activities?
The current TTM CFI of PRLD is $75.81 M
What is the all time high TTM CFI for Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated all-time high TTM cash flow from investing activities is $81.69 M
What is Prelude Therapeutics Incorporated TTM CFI year-on-year change?
Over the past year, PRLD TTM cash flow from investing activities has changed by +$116.84 M (+284.78%)